Share
JOIN OUR FREE TODAY
Join Free
Secures Strategic China Partnership and Equity Stake
Investorideas.com (www.investorideas.com newswire) a trusted platform for investing ideas including biotech stocks
issues a news and trading alert for HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing
transformative fusion immunotherapeutics to treat autoimmune disease,
cancer and senescence-associated dysplasia.
The stock makes the Nasdaq top gainer list on news, currently
trading at $1.3000 +0.9630 (+285.76%) on volume of over 198 Million
shares.
HCW Biologics reported financial results and recent business
highlights for the three months ended March 31, 2026.
Key Business Highlights
-
Major Licensing Deal Closed: Exclusive worldwide license for
HCW11-006 granted to Beijing Trimmune Biotech Co., Ltd. -
Upfront payment: $3.5 million cash (net $2.9 million after taxes)
+ $3.5 million in-kind (transferable minority equity stake in
Trimmune). - Recognized $6.5 million revenue in Q1, with $470K deferred.
-
Reagent Program Progress: Published data in Science Advances
(March 13, 2026) on HCW9206, demonstrating its potential to
improve CAR-T cell therapy manufacturing efficiency and clinical
efficacy for cancer and HIV. The company is seeking
commercialization partners. -
Clinical Pipeline: Continues advancing HCW9302 (IL-2 fusion
protein) in Phase 1 for alopecia areata (autoimmune disease), with
preliminary data expected in H1 2026.
Financial Results
(Three Months Ended March 31, 2026)
- Revenue: $6.5 million (vs. ~$5K in Q1 2025) – almost entirely from the Trimmune deal.
- R&D Expenses: $1.3 million (down 15% YoY).
- G&A Expenses: $1.8 million (down 18% YoY).
- Net Income: $3.47 million (vs. $2.2 million net loss in Q1 2025).
- Net Income Attributable to Common Stockholders: $1.98 million, or $0.37 per share.
The Company remains on track to provide preliminary clinical data
readout from the first two dose levels of the Phase 1 clinical study
evaluating HCW9302 in alopecia areata in the first half of 2026.
There are two clinical sites actively enrolling patients, and
enrollment has been on schedule. HCW9302 is an injectable,
first-in-kind interleukin 2 (“IL-2”) fusion protein complex designed
to suppress the hair-follicle killing activities of the
auto-reactive immune cells typically found in patients suffering
with alopecia areata by activating and expanding regulatory T
(“Treg”) cells. The Company has not reported any dose
limiting toxicities in the patients treated to date. With continued
patient enrollment, the full Phase 1 human data readout is expected
in the fourth quarter of 2026.
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer,
stated, “HCW9302 was selected as the lead product candidate for the
Company’s autoimmune program because it has demonstrated relatively
high IL-2Ra affinity and sustains serum exposure, which implies it
has a strong profile for the treatment of autoimmune disorders. The
Company’s preclinical studies in nonhuman primates show that HCW9302
achieves significantly longer serum half-life and exhibits strong
biological activity in relatively low doses, which could appear in
the human data readout as support for enhanced receptor selectivity,
better tolerability and reduced off-target effects.”
Full news:
HCW Biologics Reports First Quarter 2026 Business Highlights and
Financial Results
Research biotech stocks at Investorideas.com’s free stock
directory
https://www.investorideas.com/Biotech_Stocks/Stocks_List.asp
About Investorideas.com—Where you find the best investing
ideas
https://www.investorideas.com/About/
Investorideas.com is a trusted platform for retail investors, serving
as a hub for innovative investing ideas for over 25 years. Known for
its pioneering coverage of sectors like mining, cleantech, defense,
and water stocks, the company and its executives have been featured in
high-profile media outlets for its expertise. Investorideas.com is
always at the forefront of investment trends, offering coverage of
diverse industries such as AI, mining, and tech. With a mission to
empower investors, the company provides breaking news, sector-focused
articles, podcasts, and exclusive interviews with leading experts. In
addition, its award-winning branded content, AI-driven short videos,
and podcasts highlight key investing insights and feature prominent
industry leaders.
Why partner with Investor Ideas? Discover our powerful news, PR,
social media, and podcast solutions for crypto stocks at
Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Why should companies choose Investor Ideas for digital advertising and
guest posts?
https://www.investorideas.com/Advertise/
Follow us on X: @investorideas, @stocknewsbites
Follow us on Facebook:
https://www.facebook.com/Investorideas
Follow Investorideas and the Exploring Mining Podcast on YouTube:
https://www.youtube.com/c/Investorideas
Investors stay ahead by signing up for free stock news alerts at
Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
Join our free Telegram community.
https://t.me/+o8DxSAgeNCk2ZGVh
Contact us for more info
Call 800 665 0411.
Disclaimer/Disclosure Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites
should be construed as an offer or solicitation to buy or sell products
or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is
posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
More disclaimer info: More
disclaimer
and
disclosure
info
https://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
